AzTrials
AzTrials

Amyotrophic Lateral SclerosisPhase 2/3NCT04297683

HEALEY ALS Platform Trial - Master Protocol

A Phase 2/3 study testing Zilucoplan, Verdiperstat and CNM-Au8 in people with Amyotrophic Lateral Sclerosis, run by Merit E. Cudkowicz, MD at 81 sites in United States.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Amyotrophic Lateral Sclerosis
What is being tested?
Zilucoplan, Verdiperstat and CNM-Au8
Could I receive a placebo?
No, everyone receives an active treatment
How many people
1,500 participants
Where
81 sitesUnited States
Study dates
14 Jun 2020to Aug 2028
Phase
Phase 2/3
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Sporadic or familial ALS diagnosed as clinically possible, probable, lab-supported probable, or definite ALS defined by revised El Escorial criteria.
  • Age 18 years or older.
  • Capable of providing informed consent and complying with study procedures, in the SI's opinion.
  • Time since onset of weakness due to ALS ≤ 24 months at the time of the Master Protocol Screening Visit.
  • Vital Capacity ≥ 50% of predicted capacity at the time of the Master Protocol Screening Visit measured by Slow Vital Capacity (SVC), or, if required due to pandemic-related restrictions, Forced Vital Capacity (FVC) measured in person.
  • Participants must either not take riluzole or be on a stable dose of riluzole for ≥ 30 days prior to the Master Protocol Screening Visit.
Show all 9Show fewer
  • Participants must either not take edaravone or have completed at least one cycle (typically 14 days) of edaravone prior to the Master Protocol Screening Visit.
  • Participants must have the ability to swallow pills and liquids at the time of the Master Protocol Screening Visit and, in the SI's opinion, have the ability to swallow for the duration of the study.
  • Geographically accessible to the site.

Who cannot join

  • Clinically significant unstable medical condition (other than ALS) that would pose a risk to the participant, according to SI's judgment (e.g., cardiovascular instability, systemic infection), or clinically significant laboratory abnormality or EKG changes. Clinically significant abnormal liver or kidney function is exclusionary. The following values [alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 3 times the upper limit of normal (ULN) or estimated Glomerular Filtration Rate (eGFR) < 30 mL/min/1.73m2] are exclusionary regardless of clinical symptoms.
  • Presence of unstable psychiatric disease, cognitive impairment, dementia or substance abuse that would impair ability of the participant to provide informed consent, in the SI's opinion.
  • Active cancer or history of cancer, except for the following: basal cell carcinoma or successfully treated squamous cell carcinoma of the skin, cervical carcinoma in situ, prostatic carcinoma in situ, or other malignancies curatively treated and with no evidence of disease recurrence for at least 3 years.
  • Use of investigational treatments for ALS (off-label use or active participation in a clinical trial) within 5 half-lives (if known) or 30 days (whichever is longer) prior to the Master Protocol Screening Visit.
  • Exposure at any time to any gene therapies under investigation for the treatment of ALS (off-label use or investigational).
  • If female, breastfeeding, known to be pregnant, planning to become pregnant during the study, or of child-bearing potential and unwilling to use effective contraception, for the duration of the trial and for 3 months, or as specified in each RSA, after discontinuing study treatment.
Show all 9Show fewer
  • If male of reproductive capacity, unwilling to use effective contraception for the duration of the trial and for 3 months, or as specified in each RSA, after discontinuing study treatment.
  • Anything that would place the participant at increased risk or preclude the participant's full compliance with or completion of the study, in the SI's opinion.
  • If a participant is being re-screened, the disqualifying condition has not been resolved, or the mandatory wash-out duration has not occurred.

Trial locations and contacts

81 sites in 1 country.

81 sites in 1 country

United States81 sites

  • Lehigh Valley Health Network

    Allentown, Pennsylvania, 18103

  • Dent Neurologic Institute

    Amherst, New York, 14226

  • University of Michigan

    Ann Arbor, Michigan, 48109

  • Augusta University

    Augusta, Georgia, 30912

  • University of Colorado

    Aurora, Colorado, 80045

  • Austin Neuromuscular Clinic

    Austin, Texas, 78759

  • Johns Hopkins University

    Baltimore, Maryland, 21205

  • Saint Alphonsus Regional Medical Center

    Boise, Idaho, 83704

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts, 02215

  • Lahey Hospital and Medical Center

    Burlington, Massachusetts, 01805

  • University of North Carolina

    Chapel Hill, North Carolina, 27599

  • Atrium Health

    Charlotte, North Carolina, 28207

  • University of Virginia

    Charlottesville, Virginia, 22908

  • Northwestern University

    Chicago, Illinois, 60611

  • University of Chicago

    Chicago, Illinois, 60637

  • University of Cincinnati

    Cincinnati, Ohio, 45219

  • Cleveland Clinic

    Cleveland, Ohio, 44195

  • University of Missouri Health Care

    Columbia, Missouri, 65212

  • The Ohio State University

    Columbus, Ohio, 43221

  • Texas Neurology

    Dallas, Texas, 75214

  • Nova Southeastern University

    Davie, Florida, 33024

  • Henry Ford Health System

    Detroit, Michigan, 48202

  • Essentia Health

    Duluth, Minnesota, 55805

  • Duke University

    Durham, North Carolina, 27702

  • University of Kansas Medical Center

    Fairway, Kansas, 66205

  • University of Florida

    Gainesville, Florida, 32610

  • Spectrum Health/Corewell Health

    Grand Rapids, Michigan, 49525

  • Hackensack University Medical Center

    Hackensack, New Jersey, 07601

  • Virginia Commonwealth University

    Henrico, Virginia, 23233

  • Penn State Hershey

    Hershey, Pennsylvania, 17033

  • Baylor College of Medicine

    Houston, Texas, 77030

  • Houston Methodist

    Houston, Texas, 77030

  • Indiana University Health

    Indianapolis, Indiana, 46202

  • University of Iowa Hospitals and Clinics

    Iowa City, Iowa, 52242

  • Mayo Clinic Florida

    Jacksonville, Florida, 32224

  • UC San Diego

    La Jolla, California, 92037

  • Dartmouth-Hitchcock Medical Center

    Lebanon, New Hampshire, 03756

  • University of Kentucky

    Lexington, Kentucky, 40536

  • Neurology Associates, P.C./Somnos Clinical Research

    Lincoln, Nebraska, 68506

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas, 72205

  • Loma Linda University Health

    Loma Linda, California, 92354

  • Kaiser Permanente Los Angeles Medical Center

    Los Angeles, California, 90027

  • University of Southern California

    Los Angeles, California, 90033

  • Cedars-Sinai Medical Center

    Los Angeles, California, 90048

  • University of Miami

    Miami, Florida, 33136

  • Medical College of Wisconsin

    Milwaukee, Wisconsin, 53226

  • University of Minnesota Medical School

    Minneapolis, Minnesota, 55455

  • Vanderbilt University Medical Center

    Nashville, Tennessee, 37232

  • Hospital for Special Care

    New Britain, Connecticut, 06053

  • Yale University

    New Haven, Connecticut, 06519

  • Ochsner Health System

    New Orleans, Louisiana, 70115

  • Mount Sinai

    New York, New York, 10003

  • Columbia University

    New York, New York, 10032

  • University of Massachusetts Medical School

    North Worcester, Massachusetts, 01655

  • University of Nebraska Medical Center

    Omaha, Nebraska, 68198

  • University of California, Irvine

    Orange, California, 92868

  • Jefferson Weinberg ALS Center, Thomas Jefferson University

    Philadelphia, Pennsylvania, 19107

  • University of Pennsylvania

    Philadelphia, Pennsylvania, 19107

  • Lewis Katz School of Medicine at Temple University

    Philadelphia, Pennsylvania, 19140

  • Barrow Neurological Institute

    Phoenix, Arizona, 85013

  • University of Pittsburg Medical Center

    Pittsburgh, Pennsylvania, 15232

  • Providence Brain and Spine Institute ALS Center

    Portland, Oregon, 97213

  • Mayo Clinic - Rochester

    Rochester, Minnesota, 55902

  • University of Rochester

    Rochester, New York, 14642

  • University of Utah

    Salt Lake City, Utah, 84132

  • UTHSCSA

    San Antonio, Texas, 78229

  • Forbes Norris MDA/ALS Research Center, California Pacific Medical Center

    San Francisco, California, 94115

  • University of California, San Francisco

    San Francisco, California, 94143

  • Mayo Clinic Scottsdale

    Scottsdale, Arizona, 85259

  • Swedish Medical Center

    Seattle, Washington, 98122

  • University of Washington

    Seattle, Washington, 98195

  • Saint Louis University

    St Louis, Missouri, 63104

  • Washington University School of Medicine

    St Louis, Missouri, 63110

  • Stony Brook University Hospital

    Stony Brook, New York, 11794

  • SUNY Upstate

    Syracuse, New York, 13202

  • University of South Florida

    Tampa, Florida, 33612

  • Georgetown University

    Washington D.C., District of Columbia, 20007

  • George Washington University

    Washington D.C., District of Columbia, 20037

  • OhioHealth Research Institute

    Westerville, Ohio, 43082

  • Wake Forest Health Science

    Winston-Salem, North Carolina, 27157

Other trials in United States

About this study

Official title: HEALEY ALS Platform Trial

The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS.

Read the detailed description

The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS. This trial is designed as a perpetual platform trial. This means that there is a single Master Protocol dictating the conduct of the trial.

In this trial, multiple investigational products for ALS will be tested simultaneously or sequentially. Each investigational product will be tested in a regimen. Each regimen consists of a placebo-controlled trial, meaning that the active investigational product and matching placebo will be tested in each regimen.

The additional details that govern the testing of each investigational product will be summarized in separate regimen-specific appendices (RSAs). Each regimen will have a separate ClinicalTrials.gov posting, which will include specific information about the regimen. All regimen-specific outcome measures will be detailed in each regimen posting.

Participants will have an equal chance to be randomized to all regimens that are active at the time of screening. Once randomized to a regimen, participants will be randomized in a 3:1 ratio to either study drug or placebo.

The following regimens are active in the trial:

Regimen I - NUZ-001

New regimens will be continuously added as new investigational products become available. The HEALEY ALS Platform Trial will enroll additional participants as each new regimen is available.

Being tested
Zilucoplan, Verdiperstat, CNM-Au8, Pridopidine, SLS-005 Trehalose
Keywords
ALS, Placebo-Controlled, Double-Blind, Master Protocol, Lou Gehrig's Disease
Medical subject headings
Amyotrophic Lateral Sclerosis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • ZilucoplanDrug

    Drug: Zilucoplan Administration: Subcutaneous injection Dose: Minimum of .0.22 mg/kg daily to a maximum dose of 0.42 mg/kg daily, dependent on weight

  • VerdiperstatDrug

    Drug: Verdiperstat Administration: Oral Dose: 600mg twice daily

  • CNM-Au8Drug

    Drug: CNM-Au8 Administration: Oral Dose: 30 mg or 60 mg daily

  • PridopidineDrug

    Drug: Pridopidine Administration: Oral Dose: 45mg twice daily

  • SLS-005 TrehaloseDrug

    Drug: SLS-005 Trehalose Administration: Infusion Dose: 0.75 g/kg weekly

  • ABBV-CLS-7262Drug

    Drug: ABBV-CLS-7162 Administration: Oral Dose: Dose 1 or Dose 2

  • DNL343Drug

    Drug: DNL343 Administration: Oral Dose: Once per day

  • NUZ-001Drug

    Drug: NUZ-001. Administration: Oral. Dose: Once per day.

Study groups in NCT04297683
Study groupRoleWhat they receive
Regimen A - ZilucoplanExperimentalParticipants are randomized to receive either active zilucoplan or matching placebo. NO LONGER RECRUITING; RESULTS REPORTED.
Receives: Drug: Zilucoplan
Regimen B - VerdiperstatExperimentalParticipants are randomized to receive either active verdiperstat or matching placebo. NO LONGER RECRUITING; RESULTS REPORTED.
Receives: Drug: Verdiperstat
Regimen C - CNM-Au8ExperimentalParticipants are randomized to receive either active CNM-Au8 or matching placebo. NO LONGER RECRUITING; RESULTS REPORTED.
Receives: Drug: CNM-Au8
Regimen D - PridopidineExperimentalParticipants are randomized to receive either active Pridopidine or matching placebo. NO LONGER RECRUITING; RESULTS REPORTED.
Receives: Drug: Pridopidine
Regimen E - SLS-005 TrehaloseExperimentalParticipants are randomized to receive either active SLS-005 Trehalose or matching placebo. NO LONGER RECRUITING; RESULTS REPORTED.
Receives: Drug: SLS-005 Trehalose
Regimen F- ABBV-CLS-7262ExperimentalParticipants are randomized to receive either active ABBV-CLS-7262 or matching placebo. NO LONGER RECRUITING; RESULTS REPORTED.
Receives: Drug: ABBV-CLS-7262
Regimen G - DNL343ExperimentalParticipants are randomized to receive either active DNL343 or matching placebo. NO LONGER RECRUITING; RESULTS REPORTED.
Receives: Drug: DNL343
Regimen I - NUZ-001ExperimentalParticipants are randomized to receive either active NUZ-001 or matching placebo. ACTIVE, NOT RECRUITING
Receives: Drug: NUZ-001

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Disease Progression

    Change in disease severity as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R) total score and survival.

    Measured: 36 Weeks

Secondary outcomes (2)

  1. Respiratory Function

    Change in respiratory function over time as measured by Slow Vital Capacity (SVC).

    Measured: 36 Weeks

  2. Survival

    Comparison of rate of occurrence between groups.

    Measured: 36 Weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 Mar 2020
  2. Study start14 Jun 2020
  3. Primary completionJul 2027 (estimated)
  4. Study completionAug 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2/3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
As new investigational products become available, additional regimens will be added to the HEALEY ALS Platform Trial.
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
1,500 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04297683
Sponsor's protocol ID
2019P003518
Status last verified
Jul 2026
First submitted
3 Mar 2020
Last updated
21 Jul 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
No

Publications

  • Writing Committee for the HEALEY ALS Platform Trial; Berry JD, Maragakis NJ, Macklin EA, Chibnik LB, Quintana M, Saville BR, Detry MA, Vestrucci M, Marion J, McGlothlin A, Stommel EW, Chase M, Pothier L, Harkey BA, Yu H, Sherman A, Shefner J, Hall M, Kittle G, Babu S, Andrews J, D'Agostino D, Tustison E, Scirocco E, Giacomelli E, Alameda G, Locatelli E, Ho D, Quick A, Ajroud-Driss S, Katz J, Heitzman D, Appel SH, Shroff S, Felice KJ, Simmons Z, Miller T, Olney N, Weiss MD, Goutman SA, Fernandes JA Jr, Jawdat O, Owegi MA, Foster L, Vu T, Ilieva H, Newman DS, Arcila-Londono X, Jackson C, Ladha S, Heiman-Patterson T, Caress J, Swenson A, Peltier A, Lewis R, Fee D, Elliott M, Bedlack R, Kasarskis EJ, Elman L, Rosenfeld J, Walk D, McIlduff CE, Twydell P, Young E, Johnson K, Rezania K, Goyal NA, Cohen JA, Benatar M, Jones V, Glass J, Shah J, Beydoun SR, Wymer JP, Zilliox L, Nayar S, Pattee GL, Martinez-Thompson J, Rynders A, Evan J, Evan J, Hartford A, Sepassi M, Ho KS, Glanzman R, Greenberg B, Hotchkin MT, Paganoni S, Cudkowicz ME; HEALEY ALS Platform Trial Study Group. CNM-Au8 in Amyotrophic Lateral Sclerosis: The HEALEY ALS Platform Trial. JAMA. 2025 Feb 17;333(13):1138-49. doi: 10.1001/jama.2024.27643. Online ahead of print.

    PubMed 40067821

  • Writing Committee for the HEALEY ALS Platform Trial; Shefner JM, Oskarsson B, Macklin EA, Chibnik LB, Quintana M, Saville BR, Detry MA, Vestrucci M, Marion J, McGlothlin A, Heiman-Patterson T, Chase M, Pothier L, Harkey BA, Yu H, Sherman AV, Hall M, Kittle G, Berry JD, Babu S, Andrews J, D'Agostino D, Tustison E, Scirocco E, Giacomelli E, Alameda G, Locatelli E, Ho D, Quick A, Ajroud-Driss S, Katz J, Heitzman D, Appel SH, Shroff S, Felice K, Maragakis NJ, Simmons Z, Miller TM, Olney N, Weiss MD, Goutman SA, Fernandes JA, Jawdat O, Owegi MA, Foster LA, Vu T, Ilieva H, Newman DS, Arcila-Londono X, Jackson CE, Ladha S, Caress JB, Swenson A, Peltier A, Lewis RA, Fee D, Elliott M, Bedlack R, Kasarskis EJ, Elman L, Rosenfeld J, Walk D, McIlduff C, Twydell P, Young E, Johnson K, Rezania K, Goyal NA, Cohen JA, Benatar M, Jones V, Shah J, Beydoun SR, Wymer JP, Zilliox L, Nayar S, Pattee GL, Martinez-Thompson J, Leitner ML, Chen K, Goldberg YP, Cohen Y, Geva M, Hayden MR, Paganoni S, Cudkowicz ME; HEALEY ALS Platform Trial Study Group. Pridopidine in Amyotrophic Lateral Sclerosis: The HEALEY ALS Platform Trial. JAMA. 2025 Feb 17;333(13):1128-37. doi: 10.1001/jama.2024.26429. Online ahead of print.

    PubMed 40067755

  • Writing Committee for the HEALEY ALS Platform Trial; Andrews J, Paganoni S, Macklin EA, Chibnik LB, Quintana M, Saville BR, Detry MA, Vestrucci M, Marion J, McGlothlin A, Young E, Chase M, Pothier L, Harkey B, Yu H, Sherman A, Shefner J, Hall M, Kittle G, Connolly MR, Berry JD, D'Agostino D, Tustison E, Giacomelli E, Scirocco E, Alameda G, Locatelli E, Ho D, Quick A, Heitzman D, Ajroud-Driss S, Appel SH, Shroff S, Katz J, Felice K, Maragakis NJ, Simmons Z, Goutman SA, Olney N, Miller T, Fernandes JA, Ilieva H, Jawdat O, Weiss MD, Foster L, Vu T, Ladha S, Owegi MA, Newman DS, Arcila-Londono X, Jackson CE, Swenson A, Heiman-Patterson T, Caress J, Fee D, Peltier A, Lewis R, Rosenfeld J, Walk D, Johnson K, Elliott M, Kasarskis EJ, Rutkove S, McIlduff CE, Bedlack R, Elman L, Goyal NA, Rezania K, Twydell P, Benatar M, Glass J, Cohen JA, Jones V, Zilliox L, Wymer JP, Beydoun SR, Shah J, Pattee GL, Martinez-Thompson J, Nayar S, Granit V, Donohue M, Grossman K, Campbell DJ, Qureshi IA, Cudkowicz ME, Babu S. Verdiperstat in Amyotrophic Lateral Sclerosis: Results From the Randomized HEALEY ALS Platform Trial. JAMA Neurol. 2025 Apr;82(4):333-343. doi: 10.1001/jamaneurol.2024.5249. Epub 2025 Feb 17.

    PubMed 40067754

  • Paganoni S, Fournier CN, Macklin EA, Chibnik LB, Quintana M, Saville BR, Detry MA, Vestrucci M, Marion J, McGlothlin A, Ajroud-Driss S, Chase M, Pothier L, Harkey BA, Yu H, Sherman AV, Shefner JM, Hall M, Kittle G, Berry JD, Babu S, Andrews J, Dagostino D, Tustison E, Giacomelli E, Scirocco E, Alameda G, Locatelli E, Ho D, Quick A, Katz J, Heitzman D, Appel SH, Shroff S, Felice K, Maragakis NJ, Simmons Z, Miller TM, Olney N, Weiss MD, Goutman SA, Fernandes JA, Jawdat O, Owegi MA, Foster LA, Vu T, Ilieva H, Newman DS, Arcila-Londono X, Jackson CE, Ladha S, Heiman-Patterson T, Caress JB, Swenson A, Peltier A, Lewis R, Fee D, Elliott M, Bedlack R, Kasarskis EJ, Elman L, Rosenfeld J, Walk D, McIlduff C, Twydell P, Young E, Johnson K, Rezania K, Goyal NA, Cohen JA, Benatar M, Jones V, Glass J, Shah J, Beydoun SR, Wymer JP, Zilliox L, Nayar S, Pattee GL, Martinez-Thompson J, Harvey B, Patel S, Mahoney P, Duda PW, Cudkowicz ME; HEALEY ALS Platform Trial Study Group. Efficacy and Safety of Zilucoplan in Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial. JAMA Netw Open. 2025 Feb 3;8(2):e2459058. doi: 10.1001/jamanetworkopen.2024.59058.

    PubMed 39960672

Questions about this trial

What is this clinical trial studying?

A Phase 2/3 study testing Zilucoplan, Verdiperstat and CNM-Au8 in people with Amyotrophic Lateral Sclerosis, run by Merit E. Cudkowicz, MD at 81 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 9 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 21 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 81 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this combined phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Disease Progression (time frame: 36 Weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04297683, which also lists 4 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Jul 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in